BENGALURU: AstraZeneca’s Indian arm plans to sell its 64-acre manufacturing facility in North Bengaluru as part of a review of its global supply and manufacturing network by its UK-based parent company.
The land, estimated to garner around ₹3,400 crore for AstraZeneca Pharma India, has attracted interest from developers such as Sattva Group, Aurobindo Pharma, and RMZ. This sale is part of a broader land monetization initiative.
A source indicated, “AstraZeneca has shortlisted three potential bidders and plans to finalize the deal soon.” The land, located in a prime area of North Bengaluru, is valued at over ₹53 crore per acre, though previous attempts to sell were complicated by high pricing expectations.
According to an insider, “The company previously aimed to position the facility as a running asset and sought a buyer that could operate it as a contract manufacturing organization for products currently made or packaged there, pending regulatory approvals. Now, they wish to divest the land to allow for the development of residential and commercial projects.”
None of the companies involved, including AstraZeneca Pharma, Sattva, Aurobindo Pharma, and RMZ, were available for comment.
AstraZeneca’s Bengaluru facility is among nine global sites focused on clinical trial design, safety monitoring, and regulatory compliance. Established in 1979, AstraZeneca Pharma India is headquartered in Bengaluru.
This planned divestment aligns with a growing trend of companies monetizing non-core assets in response to rising land values in prominent cities such as Mumbai, Delhi, Bengaluru, Hyderabad, Chennai, and Pune.
Developers are actively seeking to acquire these land parcels to replenish their land banks, with companies like Godrej Properties and Prestige Group leading recent transactions.
